CSIMarket
 


Kymera Therapeutics Inc   (KYMR)
Other Ticker:  
 
 

KYMR's Operating Income Growth by Quarter and Year

Kymera Therapeutics Inc 's Operating Income results by quarter and year




KYMR Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -44.88 -24.73 0.00
III Quarter September -57.51 -40.81 -13.17 0.00
II Quarter June -43.38 -36.93 8.08 0.00
I Quarter March -45.33 -28.64 -8.08 0.00
FY   -146.22 -151.26 -37.90 0.00



KYMR Operating Income third quarter 2023 Y/Y Growth Comment
Kymera Therapeutics Inc in the third quarter 2023 recorded Operating Loss of $ -57.51 millions.

According to the results reported in the third quarter 2023, Kymera Therapeutics Inc achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While Kymera Therapeutics Inc ' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2023.

Explain Operating Income growth


KYMR Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Kymera Therapeutics Inc 's third quarter 2023 Operating Income $ -57.51 millions KYMR's Income Statement
Kymera Therapeutics Inc 's third quarter 2022 Operating Income $ -40.81 millions Quarterly KYMR's Income Statement
New: More KYMR's historic Operating Income Growth >>


KYMR Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Kymera Therapeutics Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYMR's III. Quarter Q/Q Operating Income Comment
Recent results of -57.51 millions by Kymera Therapeutics Inc look even more unfavourable compare to the -43.38 millions Operating Loss a quarter before.

Within Biotechnology & Pharmaceuticals industry Kymera Therapeutics Inc achieved highest sequential Operating Income growth. While Kymera Therapeutics Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYMR's III. Quarter Q/Q Operating Income Comment
Recent Operating Loss of -57.51 millions by Kymera Therapeutics Inc come out even more unfavourable compare to the -43.38 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Kymera Therapeutics Inc achieved highest sequential Operating Income growth. While Kymera Therapeutics Inc 's Operating Income growth quarter on quarter, overall rank is .


Kymera Therapeutics Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Operating Income 12 Months Ending $ -191.10 $ -174.40 $ -167.95 $ -151.26 $ -131.11
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Kymera Therapeutics Inc ' has realized cumulative trailing twelve months Operating Loss of $ -191 millions in the Sep 30 2023 period.
The situation is worsening as the cumulative Operating Loss is getting bigger from $ -174.4 millions in TTM ending quarter Jun 30 2023 and $ -103.469 millions for the twelve months ending in the quarter a year ago.

Kymera Therapeutics Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Kymera Therapeutics Inc ' has realized cumulative trailing twelve months Operating Loss of $ -191 millions in the Sep 30 2023 period.
The business is worsening as the cumulative Operating Loss is getting bigger from $ -174.4 millions for the period from Jun 30 2023 to Jun 30 2022 and $ -103.469 millions from the TTM period ending Jun 30 2022 Sierra Hill mentioned.

Kymera Therapeutics Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
KYMR's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for KYMR's Competitors
Operating Income Growth for Kymera Therapeutics Inc 's Suppliers
Operating Income Growth for KYMR's Customers

You may also want to know
KYMR's Annual Growth Rates KYMR's Profitability Ratios KYMR's Asset Turnover Ratio KYMR's Dividend Growth
KYMR's Roe KYMR's Valuation Ratios KYMR's Financial Strength Ratios KYMR's Dividend Payout Ratio
KYMR's Roa KYMR's Inventory Turnover Ratio KYMR's Growth Rates KYMR's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Amneal Pharmaceuticals Inc 70.56%$ 70.559 millions
Fonar Corporation68.01%$ 68.013 millions
Integer Holdings Corporation64.31%$ 64.314 millions
Cadre Holdings inc 62.18%$ 62.183 millions
Progyny Inc 61.61%$ 61.608 millions
Neurocrine Biosciences Inc 60.82%$ 60.820 millions
Davita Inc 59.06%$ 59.063 millions
Incyte Corporation55.16%$ 55.161 millions
Cardiff Lexington Corporation51.41%$ 51.406 millions
Lemaitre Vascular Inc 49.27%$ 49.268 millions
Msa Safety Inc46.35%$ 46.351 millions
Merck and Co Inc 43.22%$ 43.220 millions
Iradimed Corporation42.91%$ 42.907 millions
Select Medical Holdings Corp42.08%$ 42.084 millions
Semler Scientific inc 41.01%$ 41.012 millions
Dexcom Inc 39.32%$ 39.322 millions
Ir med Inc 36.64%$ 36.644 millions
Option Care Health Inc 33.48%$ 33.481 millions
Lftd Partners Inc 33.17%$ 33.168 millions
Lantheus Holdings Inc 31.04%$ 31.044 millions
Addus Homecare Corporation30.39%$ 30.389 millions
Third Harmonic Bio Inc 26.30%$ 26.304 millions
Becton Dickinson And Company25.54%$ 25.540 millions
Conmed Corporation24.96%$ 24.959 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com